← Human Trials & Peer-Reviewed Studies
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
Plain-language guide to NCT05963022: phase 3 randomized trial of Tirzepatide, 206 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT05963022
- Phase
- phase 3
- Status
- completed
- Start
- 2023-08-21
- Completion (planned or actual)
- 2024-10-09
- Participants
- 206 (actual)
- Design
- randomized, double-blind, treatment
- Conditions studied
- Type 2 Diabetes
- Results posted
- yes
What This Study Did, in Plain Language
What Was Tested
The trial (phase 3) is built around Tirzepatide.
The registry classes the interventions as drug.
Who Took Part
206 actual participants took part.
It was open to people of any sex aged from 18 years with no upper age limit.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Have Type 2 Diabetes. Have Body Mass Index (BMI) ≥23.0 kilogram per square meter (kg/m²).
The full record lists 4 inclusion and 7 exclusion criteria; among the exclusions: have type 1 diabetes; have a history of chronic or acute pancreatitis any time prior to study entry; are currently receiving treatment for diabetic retinopathy and/or macular edema.
How the Study Was Run
The set-up was randomized, parallel-group and double-blind.
Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Groups ran in parallel: each of the participants stayed in one arm throughout.
As a double-blind Tirzepatide study, the assignments were hidden from both participants and investigators until the end.
Those kept unaware of assignments: participant and investigator.
It started in 2023-08-21 with completion listed for 2024-10-09.
It ran at 28 sites in China (28).
Its stated primary purpose is treatment.
What Was Measured
Researchers chose this as the main measure: Change From Baseline in Hemoglobin A1c (HbA1c) (time frame: Baseline, Week 40).
It also tracked 9 secondary outcomes, for example Change From Baseline in Fasting Serum Glucose, Change From Baseline in Body Weight and Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose Profiles (SMBG).
What This Means in Plain Language
Put simply, this is a phase 3, randomized trial of Tirzepatide in 206 people.
The trial is marked completed; results are posted on the registry, and this page does not restate them.
More context: the Tirzepatide compound page, all human trials.
Our Notes on the Compound
Tirzepatide: A prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.